Serum core?type fucosylated prostate?specific antigen index for the detection of high?risk prostate cancer

It is known that core-type fucosylation higher in prostate cancer cells than other cell types and associated with high-risk cancer. Here, we developed an automated microcapillary electrophoresis-based immunoassay system for measuring serum fucosylated prostate-specific antigen (PSA) evaluated whether the PSA index (FPI) can detect Core-type fucosylated-free was measured by our Pholiota squarrosa lectin. The FPI calculated from total percentage of PSA. optimum model to predict Gleason grade (GG) ?2 constructed multivariate logistic regression analysis. Discrimination assessed determining area under receiver operator characteristic curve (AUC). study included 252 men who underwent needle biopsy due elevated levels (4-20 ng/mL), including 138 GG ?2. A significantly (P < .0001). Multivariate analysis showed age, volume were significant predictors AUC 0.729 (95% confidence interval [CI]: 0.668-0.790) 0.837 CI: 0.788-0.886), respectively, compared 0.629 0.561-0.698) Decision superior benefit when In a cohort <20 ng/mL, could differentiate biopsy-negative or low-risk Therefore, be useful adjunct counseling abnormal levels.